Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults

• Main Authors: Tim R. Cressey, Ram Yogev, Andrew Wiznia, Rohan Hazra, Patrick Jean-Philippe, Bobbie Graham, Amy Gonzalez, Paula Britto, Vincent J. Carey, Courtney V. Fletcher, Edward P. Acosta
• Format: Journal
• Published: 2018
• Subjects: Agricultural and Biological Sciences
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85031793814&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/43670
• Institution: Chiang Mai University

© The Author 2017. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.